• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Jorge Gomez Joins Moderna as Chief Financial Officer

    4/11/22 9:00:00 AM ET
    $CAH
    $MRNA
    $PEAR
    $XRAY
    Other Pharmaceuticals
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CAH alert in real time by email

    CAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that Jorge Gomez will join Moderna as Chief Financial Officer, effective Monday, May 9, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane Bancel.

    "I am pleased to welcome Jorge to Moderna as our Chief Financial Officer and as a member of the Executive Committee," said Mr. Bancel. "As we grow and scale the company globally, Jorge's experience leading the financial functions of multinational healthcare companies will be an asset to our team. Jorge's passion for sustainability and ESG aligns closely with Moderna's vision to make corporate responsibility a critical part of who we are and what we do. I look forward to working with Jorge as we continue to deliver on our strategic priorities to ultimately impact human health with mRNA medicines."

    Mr. Gomez joins Moderna from Dentsply Sirona, Inc. (NASDAQ:XRAY) where he served as Executive Vice President & Chief Financial Officer since August 2019. At Dentsply Sirona, he was responsible for leading the global finance organization, including strategic finance, FP&A, Accounting, Treasury, Tax, Corporate Audit and Investor Relations, and the Information Technology function. In addition, Mr. Gomez was responsible for leading Dentsply Sirona's sustainability and ESG program.

    Prior to Dentsply Sirona, Mr. Gomez spent 13 years at Cardinal Health (NYSE:CAH), a Fortune 14 company, where he most recently served as CFO and previously held positions including Medical Segment CFO, Pharmaceutical Segment CFO, Corporate Treasurer and Corporate Controller. Prior to Cardinal Health, Mr. Gomez held positions of progressive financial and business leadership at General Motors, including in New York City, Singapore, Belgium, and Brazil.

    "It is a privilege for me to join an organization that is focused on developing transformative medicines to address major public healthcare challenges worldwide," said Mr. Gomez. "I look forward to working with the team on this great mission."

    Mr. Gomez received his Master of Business Administration from the University of Hartford and his Bachelor of Science in electrical engineering from the National University of Colombia. Mr. Gomez serves on the Board of Directors for Xylem, Inc. (NYSE:XYL) and for Pear Therapeutics (NASDAQ:PEAR).

    David Meline, Moderna's current CFO, has decided to retire and will remain with the Company as a consultant to ensure a smooth transition of the CFO role to Mr. Gomez.

    "I am very thankful to David for having decided to come out of retirement in the spring of 2020 to help us get Moderna ready for commercialization in record time. Moderna was an early-stage development, U.S. focused company when David joined us. He goes back into retirement after having helped transform Moderna into a global commercial company. He has built a great team and strong financial business processes. It has been a pleasure to work with him, and I wish him and his wife a wonderful time."

    About Moderna

    In 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators. Most recently, Moderna's capabilities have come together to allow the authorized use of one of the earliest and most effective vaccines against the COVID-19 pandemic.

    Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the Company's appointment of Jorge Gomez as Chief Financial Officer and the retirement of current Chief Financial Officer, David Meline. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading "Risk Factors" in Moderna's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date hereof.

    Moderna Contacts

    Media:
    Colleen Hussey
    Senior Director, Corporate Communications
    617-335-1374
    [email protected]

    Investors:
    Lavina Talukdar
    Senior Vice President & Head of Investor Relations
    617-209-5834
    [email protected]

    SOURCE: Moderna, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/696878/Jorge-Gomez-Joins-Moderna-as-Chief-Financial-Officer

    Get the next $CAH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CAH
    $MRNA
    $PEAR
    $XRAY

    CompanyDatePrice TargetRatingAnalyst
    Cardinal Health Inc.
    $CAH
    6/3/2025$179.00Equal Weight → Overweight
    Wells Fargo
    Xylem Inc.
    $XYL
    5/30/2025$148.00Overweight
    Analyst
    DENTSPLY SIRONA Inc.
    $XRAY
    4/15/2025$14.00Overweight → Equal-Weight
    Morgan Stanley
    Moderna Inc.
    $MRNA
    3/13/2025$40.00Neutral
    Citigroup
    DENTSPLY SIRONA Inc.
    $XRAY
    3/13/2025Buy → Hold
    Needham
    Moderna Inc.
    $MRNA
    2/18/2025$111.00 → $45.00Overweight → Equal Weight
    Barclays
    DENTSPLY SIRONA Inc.
    $XRAY
    2/14/2025$20.00Equal Weight
    Wells Fargo
    Cardinal Health Inc.
    $CAH
    2/5/2025$140.00 → $150.00Hold → Buy
    Jefferies
    More analyst ratings

    $CAH
    $MRNA
    $PEAR
    $XRAY
    SEC Filings

    See more
    • SEC Form S-8 filed by DENTSPLY SIRONA Inc.

      S-8 - DENTSPLY SIRONA Inc. (0000818479) (Filer)

      7/1/25 4:21:57 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • SEC Form 11-K filed by Xylem Inc.

      11-K - Xylem Inc. (0001524472) (Filer)

      6/26/25 9:50:43 AM ET
      $XYL
      Fluid Controls
      Industrials
    • SEC Form 11-K filed by Cardinal Health Inc.

      11-K - CARDINAL HEALTH INC (0000721371) (Filer)

      6/20/25 8:32:15 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care

    $CAH
    $MRNA
    $PEAR
    $XRAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:27:16 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:24:36 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Lucier Gregory T bought $249,994 worth of shares (15,142 units at $16.51), increasing direct ownership by 23% to 81,971 units (SEC Form 4)

      4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      3/3/25 6:33:03 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $CAH
    $MRNA
    $PEAR
    $XRAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Xylem to Release Second Quarter 2025 Financial Results on July 31, 2025

      Xylem Inc. (NYSE:XYL), a leading global water solutions company that empowers customers and communities to build a more water-secure world, will release its second quarter 2025 results at 6:55 a.m. (ET) on July 31, 2025. At 9:00 a.m. (ET), Xylem's senior management team will host a conference call with investors. The call can be accessed by calling +1 (866) 777-2509 (US) or +1 (412) 317-5413 (INTL) or by visiting Investors Events | Xylem US. A replay of the briefing will be available on Investors Events | Xylem US and via telephone from July 31, 2025, 1:00 p.m. (ET) until August 14, 2025, at 11:59 p.m. (ET). The telephone replay will be available at +1 (877) 344-7529 or +1 (412) 317-008

      7/1/25 4:15:00 PM ET
      $XYL
      Fluid Controls
      Industrials
    • Flagship Pioneering Unveils Terrana Biosciences to Deliver Adaptive, Targeted Agricultural Solutions through a Novel RNA Technology Platform

      Solutions focus on enhancing crop resilience, protecting yields, and addressing critical challenges in the global food system The company emerges after four years of platform development with an initial commitment of $50 million from Flagship Pioneering CAMBRIDGE, Mass., July 1, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Terrana Biosciences™, a company pioneering RNA-based agricultural solutions to deliver protective and enhanced crop traits without altering the plant genome. Through its proprietary RNA technology platform, Terrana is developing targeted products designed to work at any time in a plant's lifecycle, enabling a continuous prod

      7/1/25 6:30:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • After Major Oncology Conference, All Eyes Turn to Industry Innovation

      USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

      6/12/25 9:00:00 AM ET
      $CAH
      $CTOR
      $CTXR
      $ONCY
      Other Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CAH
    $MRNA
    $PEAR
    $XRAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cardinal Health upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Cardinal Health from Equal Weight to Overweight and set a new price target of $179.00

      6/3/25 7:24:57 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • Analyst initiated coverage on Xylem with a new price target

      Analyst initiated coverage of Xylem with a rating of Overweight and set a new price target of $148.00

      5/30/25 8:42:01 AM ET
      $XYL
      Fluid Controls
      Industrials
    • Dentsply Sirona downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Dentsply Sirona from Overweight to Equal-Weight and set a new price target of $14.00

      4/15/25 9:24:19 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $CAH
    $MRNA
    $PEAR
    $XRAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Mazelsky Jonathan Jay

      4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      7/2/25 4:25:55 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Chief Legal/Compliance Officer Mayer Jessica L covered exercise/tax liability with 5,176 shares, decreasing direct ownership by 9% to 55,110 units (SEC Form 4)

      4 - CARDINAL HEALTH INC (0000721371) (Issuer)

      6/30/25 4:18:28 PM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • CEO, GMPD Segment Mason Stephen M covered exercise/tax liability with 5,694 shares, decreasing direct ownership by 14% to 34,977 units (SEC Form 4)

      4 - CARDINAL HEALTH INC (0000721371) (Issuer)

      6/30/25 4:17:48 PM ET
      $CAH
      Other Pharmaceuticals
      Health Care

    $CAH
    $MRNA
    $PEAR
    $XRAY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

      For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

      11/30/20 5:12:14 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CAH
    $MRNA
    $PEAR
    $XRAY
    Leadership Updates

    Live Leadership Updates

    See more
    • After Major Oncology Conference, All Eyes Turn to Industry Innovation

      USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

      6/12/25 9:00:00 AM ET
      $CAH
      $CTOR
      $CTXR
      $ONCY
      Other Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Dentsply Sirona Appoints Matthew E. Garth as Chief Financial Officer

      CHARLOTTE, N.C., May 29, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Matthew E. Garth has been appointed Executive Vice President and Chief Financial Officer, effective May 30, 2025. Mr. Garth brings nearly 30 years of proven financial management expertise to Dentsply Sirona, with a focus on driving value creation. He most recently served as Chief Financial Officer & Chief Administrative Officer of The Scotts Miracle-Gro Company, a global leader of branded consumer lawn and garden products. Prior to ScottsMiracle-Gro, Mr. Garth held numerous financial leadership roles at large, multinational companies, including Min

      5/29/25 4:30:00 PM ET
      $MTX
      $SMG
      $XRAY
      Major Chemicals
      Industrials
      Agricultural Chemicals
      Medical/Dental Instruments
    • Carlisle Companies Announces Leadership Appointments

      Carlisle Companies Incorporated (NYSE:CSL) today announced the appointment of Christopher B. Gaskill as Vice President & General Counsel for the Company. In conjunction with this appointment, Scott C. Selbach will transition to a new role as Executive Vice President, Government Relations for the Company. Mr. Selbach will also remain Secretary of the Company. Both Mr. Gaskill and Mr. Selbach will report to Chris Koch, Carlisle's Chair, President & Chief Executive Officer. Prior to joining Carlisle, Mr. Gaskill served as Executive Vice President, Chief Legal Officer, and Secretary at Summit Materials, Inc. (NYSE:SUM), where he was responsible for the company's global legal functions and ensu

      5/16/25 4:05:00 PM ET
      $CAH
      $CSL
      $SUM
      $WU
      Other Pharmaceuticals
      Health Care
      Specialty Chemicals
      Industrials

    $CAH
    $MRNA
    $PEAR
    $XRAY
    Financials

    Live finance-specific insights

    See more
    • Xylem to Release Second Quarter 2025 Financial Results on July 31, 2025

      Xylem Inc. (NYSE:XYL), a leading global water solutions company that empowers customers and communities to build a more water-secure world, will release its second quarter 2025 results at 6:55 a.m. (ET) on July 31, 2025. At 9:00 a.m. (ET), Xylem's senior management team will host a conference call with investors. The call can be accessed by calling +1 (866) 777-2509 (US) or +1 (412) 317-5413 (INTL) or by visiting Investors Events | Xylem US. A replay of the briefing will be available on Investors Events | Xylem US and via telephone from July 31, 2025, 1:00 p.m. (ET) until August 14, 2025, at 11:59 p.m. (ET). The telephone replay will be available at +1 (877) 344-7529 or +1 (412) 317-008

      7/1/25 4:15:00 PM ET
      $XYL
      Fluid Controls
      Industrials
    • Dentsply Sirona Declares Quarterly Cash Dividend

      CHARLOTTE, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on July 11, 2025, to holders of record as of June 27, 2025. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and

      5/27/25 4:15:00 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Xylem Inc. Declares Second Quarter Dividend of 40 Cents per Share

      The Board of Directors of Xylem Inc. (NYSE:XYL), has declared a second quarter dividend of $0.40 per share payable on June 26, 2025, to shareholders of record as of May 29, 2025. About Xylem Xylem (XYL) is a Fortune 500 leading global water solutions company that empowers customers and communities to build a more water-secure world. Our 23,000 diverse employees delivered revenue of $8.6 billion in 2024, optimizing water and resource management with innovation and expertise. Join us at www.xylem.com and let's solve water. View source version on businesswire.com: https://www.businesswire.com/news/home/20250514875391/en/ Media Houston Spencer +1 (914) 240-3046 [email protected] Inve

      5/14/25 4:15:00 PM ET
      $XYL
      Fluid Controls
      Industrials

    $CAH
    $MRNA
    $PEAR
    $XRAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by DENTSPLY SIRONA Inc.

      SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)

      12/6/24 10:11:29 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by DENTSPLY SIRONA Inc.

      SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)

      11/14/24 1:22:35 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by DENTSPLY SIRONA Inc.

      SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)

      11/12/24 4:23:31 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care